FDA approves Dermira's wipe for excessive armpit sweating

FDA has approved glycopyrronium (Qbrexza—Dermira) to treat excessive armpit sweating. The company said the topical cloth, which can be used once daily, works by blocking receptors responsible for sweat gland activation.

FDA has approved glycopyrronium (Qbrexza—Dermira) to treat excessive armpit sweating. The company said the topical cloth, which can be used once daily, works by blocking receptors responsible for sweat gland activation. About 10 million people are affected with the condition, known as primary axillary hyperhidrosis, which results in sweating beyond what is needed for regulating normal body temperature. Currently, Allergan's onabotulinumtoxinA (Botox) injection and other costly alternatives such as laser therapy and liposuction to remove sweat glands are used to treat the condition. Dermira expects to launch the drug this fall.